

5. (currently amended) A method for producing sophorolipids for ~~prophylaxis~~ or treatment of sepsis and septic shock in a human or animal comprising the steps of:

- a. synthesizing the sophorolipid by fermentation of *Candida bombicola* in a fermentation media to form a natural mixture of lactonic sophorolipids and non-lactonic sophorolipids; and
- b. utilizing the natural mixture for ~~prophylaxis~~ or treatment of sepsis and septic shock in a human or animal.

6. (currently amended) A method for producing sophorolipids for ~~prophylaxis~~ or treatment of sepsis and septic shock in a human or animal comprising the steps of:

- a. synthesizing the sophorolipid by fermentation of *Candida bombicola* in a fermentation media to form a natural mixture of lactonic sophorolipids and non-lactonic sophorolipids;
- b. separating the lactonic sophorolipids from the natural mixture to form a lactonic fraction and mixing all remaining fractions to form a non-lactonic fraction; and
- c. utilizing the lactonic fraction for ~~prophylaxis~~ or treatment of sepsis and septic shock in a human or animal.

7. (currently amended) A method for producing sophorolipids for ~~prophylaxis~~ or treatment of sepsis and septic shock in a human or animal comprising the steps of:

- a. synthesizing the sophorolipid by fermentation of *Candida bombicola* in a fermentation media to form a natural mixture of lactonic sophorolipids and non-lactonic sophorolipids;
- b. separating the lactonic sophorolipids from the natural mixture to form a lactonic fraction and mixing all remaining fractions to form a non-lactonic fraction; and
- c. utilizing the non-lactonic fraction for ~~prophylaxis~~ or treatment of sepsis and septic shock in a human or animal.

8. (currently amended) The method as claimed in Claim 1, wherein the sophorolipid mixture is 17-L-[(2'-O- β -D-glucopyranosyl- β -D-glucopyranosyl)-oxy]-cis-9-octadecenoate based.

Changes not noted in system

Cancelled

34. (currently amended) The application of sophorolipids for treatment of sepsis and septic shock in a human or animal, the sophorolipids being synthesized by fermentation of *Candida bombicola* in a fermentation media to form a natural mixture of lactonic sophorolipids and non-lactonic sophorolipids in combination with at least one sophorolipid selected from the group consisting of:

- a-) Sophorolipids synthesized by fermentation of *Candida bombicola* in a fermentation media to form a natural mixture of lactonic sophorolipids and non-lactonic sophorolipids;
- b-) 17-L-[(2'-O- β -D-glucopyranosyl- β -D-glucopyranosyl)-oxy]-cis-9-octadecenoate-6',6"-diacetate;
- c-) Ethyl 17-L-[(2'-O- β -D-glucopyranosyl- β -D-glucopyranosyl)-oxy]-cis-9-octadecenoate;
- d-) Hexyl 17-L-[(2'-O- β -D-glucopyranosyl- β -D-glucopyranosyl)-oxy]-cis-9-octadecenoate; and
- e-) combinations thereof,

the application comprising the steps of:

i) synthesizing the sophorolipid by fermentation of *Candida bombicola* in a fermentation media to form a natural mixture of lactonic sophorolipids and non-lactonic sophorolipids; and

ii) utilizing at least one of the natural mixture, the lactonic sophorolipids, the non-lactonic sophorolipids, and combinations thereof for treatment of sepsis and septic shock in a human or animal.

~~for prophylaxis or treatment of sepsis and septic shock in a human or animal.~~

35. (currently amended) The application of the sophorolipids as claimed in Claim 34 in combination with known agents for ~~prophylaxis or treatment of sepsis and septic shock in a human or animal.~~